THE NEW BOTOX: LAVIV
US. Reported in CosmeticsDesign-Europe.com, LAVIV is a personalised injectable anti-aging treatment, expected to have a global launch after receiving approval from the US FDA. Developed and marketed by US-based Fibrocell Science (www.fibrocellscience.com), LAVIV is made from your own skin cells which are used to target the appearance of facial lines and wrinkles.
In undamaged or younger skin, renewal of fibroblasts help to produce collagen, supporting the skin, keeping it firm and wrinkle-free. The process of LAVIV is based upon removing the fibroblasts from an area of skin behind the ear, and culturing it for 90 days to produce millions of new cells that can be injected back into the skin over the course of two or three separate treatments.
Trials found that the treatment effectively improved the appearance of nasolabial fold wrinkles (from the side of your nose to the corners of your mouth) for six months, and as this is a biological process that works over time, LAVIV is able to provide gradual and natural-looking results. The treatment is said to be longer-lasting than Botox, but is likely to cost significantly more as the production process is complex and labour intensive.
The treatment has been well tolerated by users in clinic trials in the US, with the majority of adverse events being mild to moderate and resolved within a week. Common side affects are bruising, bleeding, swelling, and acute sensitivity around the area where the injections are carried out.
LAVIV is expected to launch in selected US metropolitan areas, as manufacturing is increased and physicians are trained in how to carry out the procedure, before being launched internationally. Log on to www.mylaviv.com for further information
The Pulse is produced by LdC Media The Creative Network: www.ldcmediacreative.com
For free daily alerts on what you need and want to know, click on SUBSCRIBE TO THE PULSE
